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As defined by the World Health Organization (WHO), pharma-
covigilance encompasses a range of activities whose common
aim is to detect and prevent any possible drug-related problems.
Due to the high and increasing number of drug-safety incidents,
the pharmaceutical companies and government medical agencies
consider that pharmacovigilance activities are of vital importance
for patient safety. One of the major pharmacovigilance goals is
the early detection of adverse drug events (ADEs), negative effects
occurring while the patient takes a medicine and that may be
caused by the drug [1]. For example, if a patient participates in a
clinical trial that is assessing a drug and then suffers nausea, this
symptom must be reported as an adverse event even though the
drug may not have been the cause of the complaint. Moreover,
ADEs may occur in different healthcare settings such as hospitals
and home environments as well as during transitions between
such settings. Some studies [2] have estimated that ADEs comprise
one third of hospital adverse events, affecting 2 million hospital
stays annually in the USA. In outpatient settings, ADEs cause more
than 3.5 million healthcare professional visits and nearly 125,000
hospital admissions each year. From an economic viewpoint, such
errors increased U.S. healthcare costs by $3.5 billion in 2006.
As a subset of ADE, adverse drug reactions (ADRs) are harms
caused by a drug either directly (as a collateral effect or toxicity,
but not related to medication errors) or indirectly (as medication
errors that occur during prescribing, transcribing, dispensing,
administering, adherence, or monitoring of a drug). There are sev-
eral types of ADR not related to medication errors [2]. These
include (a) toxic effects that are produced when the action of a
drug at normal doses is too strong for a specific individual and,
consequently, the expected positive effect turns into a negative
one; (b) side effects that are similar to toxic effects (occurring by
a mechanism that is different from the explanation for the thera-
peutic effect); and (c) drug–drug interactions (DDIs), i.e., alter-
ations of the effects of a drug due to the recent or simultaneous
use of one or more other drugs.
The traditional mechanisms for pharmacovigilance have
included clinical trials and spontaneous reporting systems
intended to capture individual case reports. However, these meth-
ods suffer from important limitations. On the one hand, very few
ADRs are detected during clinical trials, mainly because the proto-
cols are designed to assess the effectiveness of drugs rather than
their safety during a limited period of time. On the other hand,while drug manufacturers are obliged to report any suspected
ADR, the use of spontaneous reporting systems is voluntary for
both physicians and patients, resulting in an underestimation of
ADRs [3]. In fact, most patients are unaware of the existence of
spontaneous reporting systems and physicians who discover ADRs
may be more interested in publishing their findings in scientific
journals than in reporting them to a central database. Therefore,
the analysis of the medical literature is becoming vital for the early
detection of ADRs. Among the sources analyzed in pharmacovigi-
lance work are the contents of drug labels, scientific publications,
and, most recently, postings on social media. In social networks
patients can access health-related content as well as connect and
collaborate with other patients looking for information regarding
health issues. Regardless of the source of the drug-related informa-
tion, language technologies have become a powerful tool to extract
new insights regarding drug safety events and their causes.
2. Information extraction as a pharmacovigilance methodology
In recent years, information extraction – an application of nat-
ural language processing (NLP) techniques to the growing amounts
of unstructured information to obtain relevant facts – has been
gaining in importance within the field of biomedicine. Research
on information extraction covers several topics such as named
entity recognition (NER), relation extraction, and text classifica-
tion; it also deals with the domain-specific semantic resources
required (dictionaries, ontologies, etc.). In addition to a growing
scientific literature with research papers in this area, several chal-
lenge campaigns have been organized to assess the state of the art
of NLP technologies applied, for example, to the extraction of DDIs
[4,5]. The community has also created BioCreative campaigns1 that
aim to promote research on text mining and information extraction
techniques applied to the biological domain. Some of their more
recent tracks have focused on topics such as chemicals [6] and the
detection and normalization of diseases [7].
Text mining and NLP methods can be used to gather significant
information on ADRs and DDIs from different and heterogeneous
textual sources, supporting researchers and clinicians with the
challenging task of improving patient safety. In 2014 we accord-
ingly planned a special issue of JBI and disseminated a call for
papers focused on technologies that could help to mine knowledge
from any text-related pharmacovigilance source. Our goal was to
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regarding NLP systems and resources related to pharmacovigi-
lance. We received a total of 27 submissions from which 13 manu-
scripts were ultimately accepted for publication after a rigorous
peer-review process. The articles were selected based on their
research contribution to the field, their innovation, and the quality
of the writing. In this special issue we accordingly offer articles
that are organized in three categories: (i) contributions related to
the construction of new annotated corpora and other datasets, as
well as the exploitation of diverse sources (such as social media)
used in detecting drug safety events, (ii) research concerning tech-
niques and algorithms for text classification, NER, and relation-
extraction tasks applied to the detection of ADRs and DDIs, and
(iii) research devoted to other application areas such as network
mining or sentiment analysis. In this introductory editorial we pro-
vide a snapshot of the superb research being done to advance the
development of resources and the application of text-mining tech-
niques for pharmacovigilance issues.
2.1. Creation of corpora to support information extraction research
Annotated corpora are needed in order to develop and test new
machine-learning NLP techniques that can be used to process
unstructured information (clinical notes, comments from social
media, scientific literature), looking for relevant facts that can be
later analyzed. In this regard, Oronoz et al. [8] have introduced
the IxaMed-GS corpus of clinical notes in Spanish. This corpus is
composed of 142,154 discharge reports from the outpatient con-
sultations of the Galdakao-Usansolo Hospital from 2008 to 2012.
Two experts in pharmacy have annotated it with entities linked
to SNOMED-CT and related to diseases (1950 diseases, 763 negated
diseases and 53 speculated diseases) and drugs (1.191 entities).
They include relations among entities that capture ADRs with
90.5% inter-annotation agreement for entities and 82.8% for events.
To test the usefulness of the corpus, a use case to classify drug–dis-
ease pairs as ADR events based on a random forest machine learn-
ing algorithm has been defined. It is important to highlight that
each language used in such studies requires language-specific
resources for training and testing NLP systems (e.g., dictionaries
with specific terminology and abbreviations used by doctors that
are sometimes local to their hospital, or dictionaries with collo-
quial terms that patients use when they talk about their health
condition, similar to the CHV (Consumer Health Vocabulary), [9],
used in English).
In this same line of research, but working on a different type of
source, Karimi et al. [10] describe CADEC, a corpus composed of
1231 messages extracted from medical forums from January
2001 to September 2013 and annotated with drugs (1800 men-
tions), adverse effects (6318), symptoms (275) and diseases (283)
linked to their corresponding concepts in controlled vocabularies,
i.e., SNOMED Clinical Terms and MedDRA. These posts are in some
cases ungrammatical and may contain inaccurate and incomplete
information; social media texts are also characterized by a high
use of patient-oriented vocabulary that is not typically contained
in any available resource.
Ayvaz et al. describe the last work in this category [11], devoted
to build a dataset with information about potential drug–drug
interactions (PDDI) that merges fourteen available sources: five
sources developed for clinical applications, four datasets developed
to train and test NLP algorithms, and five sources created to sup-
port either pharmacovigilance or bioinformatics applications. As
a result of this work, an analysis of the overlap among the data
sources has been performed, concluding that there was remarkably
little overlap. Despite this finding, several cases are identified
where information about PDDIs provided in drug-product labels
could be extended with this merged dataset. A very basic approachto integrating the PDDI dataset into an existing NLP pipeline has
been tested and it slightly improved the pipeline’s performance
by using initial datasets separately.
2.2. New methods for information extraction in support of
pharmacovigilance
The article by Yang et al. [12] presents an automatic system to
filter ADR-related posts from social media. Probably the most fre-
quently used approach in text classification is the bag-of-words
model in which texts are represented as vectors of words. How-
ever, this kind of approach has a major drawback: the very high
dimensionality of the feature space. In order to overcome this,
the authors apply the latent Dirichlet allocation (LDA) model, a
probabilistic approach that projects texts into a topic space instead
of into a term space. Such topic representation can solve the
dimensionality problem while preserving the semantic structure
of texts. Another important contribution of the work is that the
LDA model is also used to enlarge the training dataset automati-
cally from a large collection of unlabeled posts, thus overcoming
the main bottleneck of the supervised machine-learning algo-
rithms: the costly and very time-consuming process of creating
hand-labeled datasets. The system achieves state-of-the-art per-
formance when compared to benchmark methods.
Also under the hypothesis of exploiting social media data for
pharmacovigilance, Alvaro et al. [13] explore a wide set of
machine-learning algorithms for classifying tweets that describe
first-hand experiences with drugs – tweets where their authors
are telling that they took the drug. Due to the high cost and
labor-intensive task of producing a human-annotated dataset, a
principal contribution of this work is the use of crowdsourcing data
annotation for producing the datasets needed to train and test
machine-learning models. In order to check the quality of the
crowdsourcing data, their inter-annotator agreements are com-
pared to the inter-annotator agreements obtained from experi-
enced annotators, showing similar scores.
Liu and Chen [14] develop a framework for extracting ADR from
online patient forums. A set of medical lexicons is used to recog-
nize the mentions of drugs and their effects. In particular, the
authors use a consumer-health vocabulary that allows interpreting
the colloquial expressions of patients. Then, the relations between
drugs and their effects are extracted using a shortest dependency
path kernel. To discern ADRs from drug indications and negated
ADRs, the framework includes a set of rules based on semantic
information from medical and linguistic knowledge bases.
Although scientific articles are among the most used sources
for ADR detection, their metadata (such as keywords or MeSH
descriptors) have seldom been exploited. Winnenburg et al. [15]
conduct a deep analysis on how the characteristics of Medline
indexing could influence the identification of ADEs from Medline
citations. They then design a system integrating some of these
characteristics for ADE detection from Medline indexing. In par-
ticular, a baseline system is proposed to identify ADEs from Med-
line citations by the co-occurrence of MeSH descriptors describing
a drug–disease pair. Then, this baseline system is refined by the
extension of the scope of descriptors and qualifiers for ADEs
(e.g., toxicity, poisoning and contraindications) and the inheri-
tance of the ADE qualifier from a broader drug descriptor to its
children.
Unlike most systems for ADR detection, which extract informa-
tion from abstracts, the system described in the article by Xu and
Wang [16] is based on an automatic process to extract drug and
side-effect pairs from full-text articles. The system combines text
classification and lexicon-based semantic annotation in order to
locate ADRs described in the articles. The list of ADRs provided
by the system was compared to the information about side effects
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the automatic system could gather information that was largely
complementary to that maintained by the FDA.
Drug interactions are a common cause of ADRs, and thereby,
their early detection could be of great value in pharmacovigilance.
Although support vector machines (SVMs) with non-linear com-
posite kernels provided the best performance results in the
DDIExtraction challenges [4,5], these methods may not be compu-
tationally optimal. Kim et al. [17] demonstrate that a linear SVM
classifier with a rich set of lexical and syntactic features is able
to improve upon the performance of state-of-the-art methods for
the DDIExtraction task used to date. Going one step further, Abacha
et al. [19] present a machine-learning system that covers all tasks
required to extract and classify drug–drug interactions automati-
cally: drug name recognition, DDI extraction and DDI classification.
The task of drug name recognition is based on using conditional
random fields (CRF) with a set of linguistic and semantic features.
The detection and classification of DDIs is performed by a hybrid
approach that combines an SVM classifier with a set of lexical,
morphosyntactic, and semantic features and a kernel-based
method that mainly exploits syntactic information from sentences.
The two above-mentioned efforts performed their experimentation
on the DDI corpus [18], the benchmark dataset of the DDIExtrac-
tion 2013 challenge.
2.3. Related applications of NLP in pharmacovigilance
Hamed et al. [20] introduce a novel Twitter-based network
model which they call Keyword–Hashtag network (K–H). Such a
network is based on associations found among domain-specific
keywords (drugs and drug-related keywords from resources such
as MeSH and the DrugBank database3), and hashtags that were
found in tweets. The links are computed using association analysis
among the keywords and hashtags that are in the same tweets.
The main hypothesis of the work is that the network could be useful
to produce novel discoveries that have not even been published in
the biomedical literature. If a new association is detected in the K–
H network, and is not found in the biomedical resources, then it is
assessed and vetted by a domain expert. Among the discoveries,
the presence of the #Alzheimers hashtag signaled a link between
ibuprofen and marijuana that was not previously known.
There is an increasing volume of digital interaction that pro-
duces a big stream of data with meaningful information that com-
panies and organizations need to access. In networks and forums
such as PatientsLikeMe or DailyStrength, patients talk to each
other about their feelings regarding a health problem, the way
their bodies react to a given drug, how they mix different drugs
to fight against a specific disease, and many other issues related
to their health condition. In this context, Noferesti and Shamsfard
[21] introduce a method for classifying patients’ experiences into
positive or negative effects of drugs based on a knowledge base
of polar facts (FactNet4) extracted from linked data sources and
using relation extraction techniques. The challenge in this research
is that patients’ experiences are often expressed without conveying
sentiment explicitly but they do note wanted or unwanted effects
of the experience that indirectly indicate positive or negative senti-
ment. Accordingly, current approaches that require sentiment words
to be written explicitly in their comments have to be extended. The
FactNet knowledge base is used to generalize patterns and is orga-
nized in a hierarchy that is used to classify polarity. The method
has been tested on a dataset of drug reviews and achieved 80% pre-
cision in classifying user comments as positive or negative facts.2 http://labels.fda.gov.
3 http://www.drugbank.ca.
4 http://factnet.org.Finally, a complete review focused on the use of social media in
the pharmacovigilance area is provided by Sarker et al. [22]. This
article describes the increasing relevance of social media to public
health as well as the advantages and disadvantages of monitoring
public health topics using social media. A total of 22 articles have
been analyzed, providing a summary of methods and resources
used and the evaluation that was performed. Fifteen of the articles
reviewed were published in last two years, indicating the great
interest in this field. Six studies have made their annotated data-
sets publicly available. They note in this review that most popular
methods to recognize messages and comments containing ADR
mentions are based on supervised classification and dictionary-
based techniques. The authors claim that more social media cor-
pora should be available to train and test NLP techniques. More-
over, they introduce a potential pathway to ADR monitoring from
social media.
3. Conclusions
The application of NLP and text mining to pharmacovigilance is
a fascinating research area that poses many unsolved problems
and opportunities for the research community. This special issue
brings out much of the relevant work done that deals with NLP
techniques and the semantic resources required to process, in an
intelligent way, the growing amounts of data in different media
(scientific publications, social media, and electronic health
records).
The papers in this special issue present a snapshot of the cur-
rent empirical and theoretical work on information extraction
methods applied to unstructured information in the field of phar-
macovigilance. Topics range from evaluation of supervised
machine learning techniques used in NER and relation extraction
(mainly detection on ADRs and DDIs) from the aforementioned
sources, NLP architectures, corpora, semantic resources, and other
applications (e.g., sentiment analysis). It is our goal that the articles
presented will be a valuable resource that helps researchers to
understand the complexity of this field and to provide an excellent
starting point for advances in the development of improved and
efficient NLP systems. Future work will face many remaining chal-
lenges, including adapting techniques to cope with additional
information (for example, patient characteristics, dosages or tem-
poral information, among others) and different text styles, populat-
ing ontologies (for example, the DINTO5 ontology [23], which is the
most comprehensive ontology of DDIs developed so far), and produc-
ing terminological resources with patient-oriented and medically-
oriented vocabularies from available data.
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